calaspargase pegol sold brand name asparlas medication treatment acute lymphoblastic leukemia approved united states component multiagent chemotherapeutic regimen pediatric young adult patients aged one month calaspargase pegol engineered protein consisting e coliderived enzyme lasparaginase ii conjugated succinimidyl carbonate monomethoxypolyethylene glycol lasparaginase portion hydrolyzes lasparagine laspartic acid depriving tumor cell lasparagine needs conjugation pegol group increases halflife drug making longer acting common incidence grade adverse reactions elevated transaminase increased bilirubin pancreatitis abnormal clotting december calaspargase pegolmknl approved united states component multiagent chemotherapeutic regimen acute lymphoblastic leukemia pediatric young adult patients age one month approval based demonstration achievement maintenance nadir serum asparaginase activity level uml using calaspargase pegolmknl intravenously every three pharmacokinetics calaspargase pegolmknl studied administered combination multiagent chemotherapy subjects bcell lineage fda approved calaspargase pegolmknl based evidence primarily two clinical trials trial trial subjects acute lymphoblastic leukemia trials conducted united states trial enrolled subjects years old recently diagnosed lymphoblastic subjects received calaspargase pegolmknl pegaspargase drug helps convert asparagine substances part combination drugs used treatment trial subjects received calaspargase pegolmknl pegaspargase intravenously day first subjects received either calaspargase pegolmknl intravenously every weeks doses pegaspargase intravenously every weeks doses second benefit calaspargase pegolmknl assessed measuring activity level asparaginase blood days first phase comparing trial enrolled subjects years old recently diagnosed highrisk subjects received one doses calaspargase pegolmknl pegaspargase intravenously part combination drugs used subjects received calaspargase pegolmknl pegaspargase day first phase days second subjects received doses calaspargase pegolmknl pegaspargase intravenously depending bone marrow benefit calaspargase pegolmknl assessed measuring concentration drug body days auc maximum amount drug blood single dose auc cmax calaspargase pegolmknl compared calaspargase pegolmknl received fda orphan drug approval granted servier pharmaceuticals httpsenwikipediaorgwikicalaspargasepegol